|D004700||Endocrine System Diseases NIH||0.71|
|D008659||Metabolic Diseases NIH||0.58|
|D044882||Glucose Metabolism Disorders NIH||0.58|
There is one clinical trial.
The infection caused by COVID19 worldwide makes it necessary to monitor drugs administered for the treatment of patients hospitalized with SARS-CoV-2. In order to know more about the efficacy and safety of the treatments used, researchers from the Cantabrian health service have developed an observational study, in the form of an ambispective registry, in which clinical data from patients treated with the different drugs currently recommended by the Spanish Agency of Medicines and Health Products (SAMHP) and the Ministry of Health, or others that may arise, are collected and analyzed. Although the conduct of clinical trials is a priority at this time, we cannot lose the clinical experience that is currently being generated, which may allow us to improve the therapeutic strategies for future patients.
Description: measured in terms of clinical stabilityMeasure: Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice Time: 6 months
Description: measured in terms of clinical recoveryMeasure: Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice Time: 6 months
Description: measured in terms of clinical mortality.Measure: Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice Time: 6 months
Description: to know the use according to the Ministry of Health Technical DocumentMeasure: Information on the patterns of use of these drugs (dose, duration of treatment, Time: 8 months
Description: Adverse effects of the medicines usedMeasure: Adverse events Time: 8 months
Description: Determine the evolution of the treatmentsMeasure: Treatments for SARS-CoV-2 positive patients not described in the protocol Time: 8 months
Description: It is composed of 10 items, with scores from 0 (worst health) to 100 points (best health)Measure: healthy survey for patients after their recovery/discharge from hospital. Time: 6 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports